253 431

Cited 0 times in

진행성 요로상피암에서 Gemcitabine과 Cisplatin 병합요법의 혈액학적 독성

DC Field Value Language
dc.contributor.author홍창희-
dc.date.accessioned2015-07-15T16:56:02Z-
dc.date.available2015-07-15T16:56:02Z-
dc.date.issued2003-
dc.identifier.issn0494-4747-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/113890-
dc.description.abstractPURPOSE: To evaluate the hematologic toxicity of gemcitabine and cisplatin (GC) in patients with advanced transitional cell carcinomas. MATERIALS AND METHODS: From 25 patients, with advanced transitional cell carcinomas, 8 had previously received M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for a metastatic disease, and were scheduled to receive gemcitabine, 1,000mg/m2, intravenously, over 30 minutes, on days 1, 8 and 15, and cisplatin, 70mg/m2, over 1 hour, on day 2 of a 28-day cycle. The hematological toxicities of each cycle were evaluated. RESULTS: The main hematological toxicities were thrombocytopenia (grade 3 in 24% and grade 4 in 16% of patients), leukopenia (grade 3 in 14% of patients) and anemia (grade 3 in 12% of patients). Four of the patients that experienced grade 4 thrombocytopenia had a tendency for recurring grade 4 thrombocytopenia during the GC chemotherapy. However, there was no evidence of bleeding. CONCLUSIONS: The most severe hematological toxicity of the GC chemotherapy was thrombocytopenia. The careful observation of the patients that experience grade 4 thrombocytopenia is recommended.-
dc.description.statementOfResponsibilityopen-
dc.format.extent672~676-
dc.relation.isPartOfKOREAN JOURNAL OF UROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHGemcitabine-
dc.subject.MESHCarcinoma-
dc.subject.MESHtransitional cell-
dc.subject.MESHToxicity-
dc.subject.MESHHematology-
dc.title진행성 요로상피암에서 Gemcitabine과 Cisplatin 병합요법의 혈액학적 독성-
dc.title.alternativeHematologic Toxicity of Gemcitabine and Cisplatin Combination Therapy in Advanced Urothelial Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨기과학)-
dc.contributor.googleauthor장창식-
dc.contributor.googleauthor조진선-
dc.contributor.googleauthor정병수-
dc.contributor.googleauthor홍창희-
dc.contributor.googleauthor김성용-
dc.contributor.googleauthor양대열-
dc.contributor.googleauthor이영구-
dc.contributor.googleauthor이상곤-
dc.identifier.doiOAK-2003-00730-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA04447-
dc.relation.journalcodeJ02135-
dc.subject.keywordGemcitabine-
dc.subject.keywordCarcinoma-
dc.subject.keywordtransitional cell-
dc.subject.keywordToxicity-
dc.subject.keywordHematology-
dc.contributor.alternativeNameHong, Chang Hee-
dc.contributor.affiliatedAuthorHong, Chang Hee-
dc.rights.accessRightsfree-
dc.citation.volume44-
dc.citation.number7-
dc.citation.startPage672-
dc.citation.endPage676-
dc.identifier.bibliographicCitationKOREAN JOURNAL OF UROLOGY, Vol.44(7) : 672-676, 2003-
dc.identifier.rimsid41465-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.